BICO’s Q4 report broadly aligned with our estimates, showing slightly negative organic growth and adjusted EBITDA profitability of 12.5%. Performance was supported by a strong quarter in Lab Automation, while Life Science Solutions faced some headwind and tough comps. Despite execution risks inherent to a turnaround, from an EV/S perspective the stock remains conspiciously cheap, trading at <1x 2026e, which is far below medtech peers.
LÄS MER
